Protalix BioTherapeutics
PLX
15 hedge funds and large institutions have $2.12M invested in Protalix BioTherapeutics in 2019 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 17 closing their positions.
800% more call options, than puts
Call options by funds: $9K | Put options by funds: $1K
53% more capital invested
Capital invested by funds: $1.38M → $2.12M (+$737K)
3.9% more ownership
Funds ownership: 0.45% → 4.36% (+3.9%)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
52% less funds holding
Funds holding: 31 → 15 (-16)
94% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MWPCG
Measured Wealth Private Client Group
Portsmouth,
New Hampshire
|
+$84.5K |
| 2 |
Jane Street
New York
|
+$77.1K |
| 3 |
Renaissance Technologies
New York
|
+$35.9K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$5 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Group One Trading
Chicago,
Illinois
|
-$43.1K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$42K |
| 3 |
WS
Wedbush Securities
Los Angeles,
California
|
-$30K |
| 4 |
JGC
J. Goldman & Co
New York
|
-$25K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$16.5K |
PLX Hedge Fund Activity: Q4 2019 in Review
15 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q4 2019, worth a combined $2.12M — up 53% from $1.38M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of PLX and 1 opened new positions — a net loss of 16 holders — while 4 trimmed existing stakes and 3 added.
The largest buyer was Measured Wealth Private Client Group, adding an estimated $84.5K. The largest seller was Group One Trading, cutting an estimated $43.1K.
- 15 institutional investors held Protalix BioTherapeutics (PLX) as of Q4 2019, down from 31 in Q3 2019.
- Funds reported $2.12M of Protalix BioTherapeutics stock for Q4 2019, up 53% quarter-over-quarter.
- 1 fund opened new Protalix BioTherapeutics positions in Q4 2019 and 17 closed out, a net change of -16 holders.
- The largest Protalix BioTherapeutics buyer in Q4 2019 was Measured Wealth Private Client Group, an estimated $84.5K added.
- The largest Protalix BioTherapeutics seller in Q4 2019 was Group One Trading, an estimated $43.1K sold.
Based on aggregated 13F filings for Q4 2019.